Benefit of revascularization for stable ischaemic heart disease: the jury is still out.
Hôpital Bichat, Cardiologie, AP-HP, Paris, France.
Amir-Ali
AA
Fassa
William
W
Wijns
Philippe
P
Kolh
Philippe Gabriel
PG
Steg
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D053805:Fractional Flow Reserve, Myocardial / Q000502:physiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000628:therapy*; D009204:Myocardial Revascularization; D018579:Patient Selection; D062645:Percutaneous Coronary Intervention; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors